愛思益普已建立了400+激酶

我們的優勢：

• 激酶種類多：目前已建成激酶庫超過400個并不斷擴大，覆蓋常用酪氨酸激酶及常見突變激酶； 

• 檢測準確：對于已有明確特異抑制劑的激酶選用其特異性抑制劑建立試驗模型，控制IC50差異與文獻報道值在5倍以內，最大不超過七倍； 

• 檢測周期短：化合物檢測出報告周期3-5個工作日，1-2個工作日可提交數據；

• 檢測方法：TR-FRET(LANCE Ultra, LathaScreen, HTRF)，熒光法(Kinase-Glo, ADP-Glo)，Z`-LYTE，Binding assay等。

愛思益普已建立的激酶列表

部分驗證數據（需要更多驗證數據請聯系我們）

參考文獻：

[1]. SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples. Cancer Chemother Pharmacol. 2009 Sep;64(4):723-32.

[2]. Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases. J Immunol. 2013, 191(7), 3568-3577.

[3].Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/Aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia. J Med Chem. 2012 Oct 25;55(20):8721-34.

[4]. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004 Nov;3(11):1427-38.

[5]. Peng SB, et al. Kinetic characterization of novel pyrazole TGF-beta receptor I kinase inhibitors and their blockade of the epithelial-mesenchymal transition. Biochemistry, 2005, 44(7), 2293-2304.